Akten

Akten is a brand name of lidocaine ophthalmic, approved by the FDA in the following formulation(s):

AKTEN (lidocaine hydrochloride - gel; ophthalmic)

• 
  Manufacturer: AKORN
  
  Approval date: October 7, 2008
  
  Strength(s): 3.5% ^[RLD]

Has a generic version of Akten been approved?

No. There is currently no therapeutically equivalent version of Akten available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Akten. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Akten.

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • October 7, 2011 - NEW DOSAGE FORM
  
  

See also...

• Akten Consumer Information (Drugs.com)
• Akten Gel Consumer Information (Wolters Kluwer)
• Akten Advanced Consumer Information (Micromedex)
• Lidocaine Gel Consumer Information (Wolters Kluwer)
• Lidocaine Ophthalmic Advanced Consumer Information (Micromedex)